Die Wirksamkeit des GLP-1 Analogons Liraglutid hinsichtlich von Blutzuckereinstellung und Gewichtsreduktion bei Patienten, die gleichzeitig mit Metformin und Rosiglitazon behandelt wurden: Eine randomisierte, doppelblinde, plazebokontrollierte Studie

Zinman, B.; Gerich, J. E.; Buse, JB; Lewin, A.; Schwartz, S; Raskin, P.; Hale, PM; Zdravković, Milan; Blonde, Lawrence

doi:10.1055/s-0029-1221934

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first incretin analogs exenatid [56], lixisenatid, liraglutide were used in persons with T2D to improve metabolic control and to reduce body mass -mostly when HbA1c exceeded 60 mmol/mol, BMI was over 35 kg/m2 and oral antidiabetic drugs failed. Their beneficial metabolic and cardiovascular effects were described recently in RCTs LEAD 1 -LEAD 6 [57][58][59][60][61][62] and LEADER. [63] We had the option to confirm their benefits in several persons.…”

Section: Case Reports Targeting Incretin Analogs/glp-1 Receptor Agonistsmentioning

confidence: 99%

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

Chlup¹,

Kaňa²,

Hanáčková³

et al. 2021

Type 2 Diabetes - From Pathophysiology to Cyber Systems

View full text Add to dashboard Cite

This overview summarizes the evolution of pathophysiologic treatment of diabetes type 2 (T2D) in the period of the last 40 years. Randomized Controlled Trials (RCT) and Real World Evidence (RWE) studies resulted in recent Statements of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) in the year 2020. Case reports and studies of a single-centre in Czech Republic are reported. The authors demonstrate the impact of (1) multiple doses of rapid insulin, (2) multiple doses of rapid or ultrarapid insulin analogs (3) continuous subcutaneous insulin infusion (CSII) (4) incretin receptor agonists, (5) fixed combination of insulin degludec with liraglutide (IDegLira) and (6) SGLT2 inhibitor dapagliflozin, on plasma glucose concentration, HbA1c, body mass and patient satisfaction. The importance of therapeutic patients´ education and technology (personal glucometers, continuous/flash glucose monitors, insulin pens/pumps) is emphasized. Most of the observations were already published. Hence, individually adopted education, lifstyle, technical equipment, incretin receptor agonists and/or metformin and/or gliflozins and/or insulin analogs appear to be the core of an effective pathophysiologic approach. Scientific conclusions from RCTs, RWE trials and own clinical case reports may prevail over clinical inertia and induce early implementation of effective methods into routine T2D treatment.

show abstract

Section: Case Reports Targeting Incretin Analogs/glp-1 Receptor Agonistsmentioning

confidence: 99%

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

Chlup¹,

Kaňa²,

Hanáčková³

et al. 2021

Type 2 Diabetes - From Pathophysiology to Cyber Systems

View full text Add to dashboard Cite

show abstract

Die Wirksamkeit des GLP-1 Analogons Liraglutid hinsichtlich von Blutzuckereinstellung und Gewichtsreduktion bei Patienten, die gleichzeitig mit Metformin und Rosiglitazon behandelt wurden: Eine randomisierte, doppelblinde, plazebokontrollierte Studie

Cited by 1 publication

References 0 publications

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020

Contact Info

Product

Resources

About